Elbert Chiang is Vice President, Head of Intellectual Property at Beam Therapeutics. Beam Therapeutics is advancing the use of base editing to develop precision genetic medicines, including programs in Alpha-1 antitrypsin deficiency and Sickle cell disease. Elbert is involved in supporting Beam’s therapeutic programs, advising on global patent preparation and prosecution strategy, building the company’s intellectual property portfolio, and providing legal support to research and business.
